Article

Pleiad chooses OmniComm and plans to use ophthalmology trial

As part of a partnership with OmniComm Systems Inc., Pleiad Devices will take advantage of the TrialMaster, an upcoming ophthalmology trial.

Fort Lauderdale, FL-Pleiad Devices has chosen OmniComm Systems Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials as its preferred vendor. Pleiad is an international Medical Device Contract Research Organization (CRO) with offices located in Europe and the United States and as a part of this partnership Pleiad will take advantage of the TrialMaster, an upcoming ophthalmology trial.

"Pleiad's clinical research team has years of experience in designing, organizing and managing clinical projects for medical device companies," said Stephen Brandao, vice president of business development for Pleiad Devices. "Over the years, our team has had experience with most of the EDC vendors in the marketplace. TrialMaster is one of the best EDC products that we have seen and we look forward to offering our medical device customers this premier service."

"Our CRO Preferred Program offers companies like Pleiad a true partner that will deliver the ancillary services that CROs need to be competitive in the evaluation process such as co-marketing and sales support for EDC. We offer the consummate partnership, both comprehensive company support and delivery of a first class EDC product," said Stephen Johnson, executive vice president of business development, services and client services and support. "At OmniComm, we are confident that our partnerships with CROs like Pleiad will ensure quality deliverables for the clinical research clients that we serve."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.